Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors [PDF]
, 2002 Michael J. Mastrangelo +1 more
openalex +1 more source
Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances
Molecular Therapy: Oncolytics, 2019 Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng +3 more
doaj
Virotherapy for cancer: Current status, hurdles, and future directions [PDF]
, 2002 David H. Kirn
openalex +1 more source
Patient-derived tumoroids and proteomic signatures: tools for early drug discovery
Frontiers in ImmunologyOnco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties.
Hélène Lê +11 more
doaj +1 more source
922. Engineering of Oncolytic Adenoviruses for Targeted and Efficient Virotherapy of Malignant Melanoma [PDF]
, 2003 openalex +1 more source
Stem Cells International, 2017 Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors.
R. Moreno +6 more
doaj +1 more source
Viruses, 2015 Oncolytic virotherapy for cancer is an innovative therapeutic option where the ability of a virus to promote cell lysis is harnessed and reprogrammed to selectively destroy cancer cells.
Janice Kim +3 more
doaj +1 more source
77. Production and Purification of Measles Virus for Oncolytic Virotherapy Clinical Trials [PDF]
, 2004 Dhanalakshmi Chinnasamy +5 more
openalex +1 more source
327. Retargetable Oncolytic Measles Viruses for Cancer Virotherapy [PDF]
, 2004 Takafumi Nakamura +3 more
openalex +1 more source
Effective gene–virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5 [PDF]
, 2005 Xin‐Yuan Liu +9 more
openalex +1 more source